Localised non-Hodgkin's lymphoma: the Sheffield Lymphoma Group experience (1970-1995).

Dobson, Leonard; Hancock, Helen; Bright, N.; Robinson, Michael H.; Hancock, Barry W.

doi:10.3892/ijo.13.6.1313

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-Hodgkin's lymphoma presents as a primary osseous lesion in <1% of cases (1), and accounts for only 4% of localised extranodal lymphomas (2). Since its recognition by Parker and Jackson in 1939 as a clinicopathological entity (3), knowledge has been expanded by numerous studies.…”

Section: Introductionmentioning

confidence: 99%

Primary bone lymphoma: A retrospective analysis

Horsman

Thomas²,

Hough³

et al. 2006

Int J Oncol

View full text Add to dashboard Cite

The aim of this study was to retrospectively define those patients with unequivocal primary bone lymphoma presenting to the Sheffield Lymphoma Group and document patient and tumour characteristics and management strategies, and correlate these with survival. Thirty-seven patients were documented from a total of 3148 cases of non-Hodgkin's lymphoma seen over 34 years. There were 17 males and 20 females, with a mean age of 55.4 years (range, 27-78). Pain was the most commonly presented symptom (67.5%), and the pelvis was the most frequently presented site (21.3%). Grade 2 and diffuse large B cell lymphoma comprised the majority of histologies (78.7% and 70.3%, respectively). Treatment was most often with radiotherapy alone (41.8%) or combined with CHOP-like chemotherapy (37.9%). The overall response rate was 56.7%, and 5-and 10-year survival rates were 64.5% and 49.6%, respectively. Univariate analysis showed an age of <60 years and complete response to be favourable prognostic factors. There was a trend toward better survival with combined modality therapy involving CHOP-like chemotherapy. Bone lymphoma has a better survival than other extranodal lymphomas. Younger age and complete response are favourable predictive factors. Combined modality treatment is likely to be the treatment of choice but this remains to be confirmed in large prospective multicentre studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary bone lymphoma: A retrospective analysis

Horsman

Thomas²,

Hough³

et al. 2006

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…About one third of patients with non-Hodgkin's lymphoma (NHL) present lymphomas at extranodal sites, such as gastroenteric tract (esophagus, stomach, bowel), sinonasal tract, bladder, liver, spleen, bone marrow and other sites (Liang et al, 1995;Dobson et al, 1998). Secondary involvement of the adrenal gland has been reported to occur in 4 % of radiographically assessed cases (Paling et al, 1983), and in 25 % of autoptic studies (Rosemberg et al, 1961).…”

Section: Introductionmentioning

confidence: 99%

A Primary Adrenal Non-Hodgkin's Lymphoma Presenting as an Incidental Adrenal Mass

Libé

Giavoli

Barbetta

et al. 2006

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The primary adrenal localization of a non-Hodgkin's lymphoma (NHL) is a rare event. We report the case of a 70-yr-old woman, who was admitted at our Institute for a hormonal evaluation after the incidental discovery of a right adrenal mass during ultrasonography (US) performed for cardiovascular disease. At the physical examination, no sign of adrenal hyperfunction was present. She showed only an androgenetic alopecia and her blood pressure was 180/70 mm Hg, with an arrhythmic heart rate of 100 beats/min. No alterations in hormonal and biochemical data were observed. US studies showed a right adrenal mass (major diameter 16 mm), and an abdominal computed tomography (CT) scan confirmed this solid lesion (major diameter 15 mm) with a high density. [75Se] methylnorcholesterol adrenal scintigraphy exhibited a normal symmetrical radiotracer uptake. After 8 months of follow-up, an abdominal CT scan demonstrated a significant increase of the right adrenal mass (major diameter: 40 mm), with a solid tissue density and enhancement after i.v. contrast. [75Se] methylnorcholesterol adrenal scintigraphy showed an absent uptake on the right side versus the contralateral side. The hematological, hormonal and radiological evaluation did not reveal any sign of malignancy. Owing to the mass enlargement and the modification of scintigraphic pattern, the patient underwent unilateral adrenalectomy. Histological examination revealed a primary diffuse large B-cell NHL (REAL classification) of the adrenal gland. After surgery, she underwent a combined polychemotherapy (cyclophospamide, adriamycin, vincristine and prednisone) and subsequently one cycle of radiotherapy. At present, the patient is in good conditions and there are no signs or symptoms of recurrent disease.

show abstract